Wearlinq
San Francisco, US · Delaware corporation · 50 employees on LinkedIn · 14 known investors
Wearlinq develops the eWave, a wireless, FDA-cleared 6-lead continuous ECG cardiac monitor with a patient smartphone app and the LiveLinq platform for clinicians to review ECG waveforms and reports. Its products serve cardiologists and clinical teams for continuous cardiac monitoring and diagnostic reporting.
Also known as WearLinq · Wearlinq Labs
Founders & leadership
Board
Investors · 14
-2.png)
Also in the syndicate · 9
Reported raises · per SEC filings
Form D private placements$11.6M disclosed across 1 of 2 rounds · 2025
▶$11.6MraisedMay 2025 · 26 investors · Other TechnologyRule 506(b)
- Yuxin LiuExecutive Officer, Director
- Michael TorresExecutive Officer
- Krish W. RamaduraiDirector
- Konrad MorzkowskiExecutive Officer, Director
- Joseph KnightDirector
- Chris DanielExecutive Officer
- Offering amount
- $18.4M
- Amount sold
- $11.6M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Wearlinq (also presented as Wearlinq Labs) is a San Francisco-based developer of wearable cardiac monitoring and diagnostic products. Its core device, eWave, is described by the company as the first wireless, continuous, FDA-cleared 6-lead multimodal ECG monitor; it is FDA 510(k)-cleared, operates for more than five days between charges, and is designed for discreet continuous wear to support patient compliance. The six distinct leads are intended to give clinicians a multidimensional view of the heart compared with single-lead monitoring.
Around the device, Wearlinq provides a patient mobile application that connects over Bluetooth to the patient's own compatible smartphone (a relay device can be supplied instead), offering a digital diary that matches EKG strips to patient-reported events, connectivity checks prompting patch replacement, continuous data transmission, and 24/7 concierge support for app setup and patch application. Clinicians access studies through LiveLinq, a full-disclosure review platform that displays ECG waveforms beat by beat across modalities including Extended Holter, with configurable displays and zoom for signal-level analysis. Wearlinq also operates an IDTF (independent diagnostic testing facility) staffed by Certified Cardiographic Technicians with round-the-clock coverage, producing daily STAT reports and study reports with turnaround the company states is often before the monitor is returned, and under 48 hours per its Series A announcement.
Business model
Wearlinq combines a wearable diagnostic device with software (LiveLinq clinician platform and a patient app) and an in-house independent diagnostic testing facility that produces the interpretive reports delivered to prescribing clinicians.
Traction
The company states eWave is FDA 510(k)-cleared and has been used across thousands of patients, and that its IDTF operation reflects thirty-three years of patient care with round-the-clock coverage by Certified Cardiographic Technicians.
Latest developments
In December 2025 Wearlinq announced a $14 million Series A led by AIX Ventures alongside $5 million in venture debt. The company also announced it was leading a roundtable discussion at HRX on September 18.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions eWave as the first wireless, continuous, FDA-cleared 6-lead multimodal ECG monitor and the lightest ECG monitor, contrasting six-lead visibility against conventional monitoring; used to detect arrhythmias with stated plans to extend to additional clinical indications such as heart failure management and remote patient monitoring.
Technology
A lightweight, wireless 6-lead continuous ECG patch monitor (eWave) with 5+ day battery life, Bluetooth pairing to a patient's personal smartphone or a supplied relay, near-real-time data transmission (data available approximately every two minutes while connected), and the LiveLinq web platform for full-disclosure waveform review across modalities including Extended Holter.
Go-to-market
Direct engagement with clinicians and healthcare professionals through inquiry-based contact on its website, supported by conference presence (a roundtable at HRX) and concierge patient onboarding services.
Clinicians and healthcare professionals prescribing cardiac monitoring, along with their patients; the company also invites general healthcare-professional and patient inquiries via its site.
Geography
Headquartered in San Francisco, California, with a US toll-free support line; heart disease in the United States is cited as its primary market focus.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlap
Companies competing with Wearlinq for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsWearlinq announced a $14 million Series A round led by AIX Ventures with participation from SpringTide, Berkeley Catalyst Fund, Lightscape Partners, Solasta, Alumni Ventures, Amino Capital, Angelschool, LDV Partners, Maliam, XB Ventures, Celtic House Asia Partners Health, Device of Tomorrow Capital, NYX Ventures Partners and SmartLink Partners.
$14M source ↗
In addition to the equity round, the company raised $5 million in venture debt to support growth.
$5M source ↗
The eWave wireless 6-lead ECG monitor is stated to be FDA 510(k)-cleared.
The company announced it was leading a roundtable discussion at HRX on September 18 at 2pm ET.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 4
primary sources listed
- Wearlinqwearlinq.com · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Wearlinq do?
- Wearlinq makes eWave, an FDA-cleared wireless 6-lead continuous ECG monitor paired with a clinician review platform.
- Who are Wearlinq's investors?
- Wearlinq's investors include AIX Ventures, Aju IB Invesment Corporation, Amino Capital, Celtic House Asia Partners, Healthtech Capital.
- How much funding has Wearlinq raised?
- Wearlinq has disclosed $11.6M raised across 1 of its 2 known rounds.
- Where is Wearlinq headquartered?
- Wearlinq is headquartered in San Francisco, US.